image
Healthcare - Biotechnology - NASDAQ - US
$ 0.982
-18.1 %
$ 113 M
Market Cap
-0.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one FATE stock under the worst case scenario is HIDDEN Compared to the current market price of 0.982 USD, Fate Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one FATE stock under the base case scenario is HIDDEN Compared to the current market price of 0.982 USD, Fate Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one FATE stock under the best case scenario is HIDDEN Compared to the current market price of 0.982 USD, Fate Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart FATE

image
$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.515 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
13.6 M REVENUE
-78.55%
-210 M OPERATING INCOME
-10.37%
-186 M NET INCOME
-15.74%
-123 M OPERATING CASH FLOW
7.10%
12.2 M INVESTING CASH FLOW
-89.16%
99.9 M FINANCING CASH FLOW
117420.00%
1.86 M REVENUE
-39.49%
-61.7 M OPERATING INCOME
-17.89%
-52.2 M NET INCOME
-9.39%
-27.8 M OPERATING CASH FLOW
5.51%
22.8 M INVESTING CASH FLOW
-10.39%
3.13 M FINANCING CASH FLOW
0.00%
Balance Sheet Fate Therapeutics, Inc.
image
Current Assets 292 M
Cash & Short-Term Investments 279 M
Receivables 3.54 M
Other Current Assets 9.3 M
Non-Current Assets 149 M
Long-Term Investments 27.7 M
PP&E 111 M
Other Non-Current Assets 10.2 M
63.32 %6.28 %25.16 %Total Assets$440.7m
Current Liabilities 38.5 M
Accounts Payable 9.36 M
Short-Term Debt 7.42 M
Other Current Liabilities 21.7 M
Non-Current Liabilities 83.4 M
Long-Term Debt 0
Other Non-Current Liabilities 83.4 M
7.68 %6.08 %17.83 %68.42 %Total Liabilities$122.0m
EFFICIENCY
Earnings Waterfall Fate Therapeutics, Inc.
image
Revenue 13.6 M
Cost Of Revenue 19 M
Gross Profit -5.33 M
Operating Expenses 224 M
Operating Income -210 M
Other Expenses -24 M
Net Income -186 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)14m(19m)(5m)(224m)(210m)24m(186m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-39.11% GROSS MARGIN
-39.11%
-1542.63% OPERATING MARGIN
-1542.63%
-1366.46% NET MARGIN
-1366.46%
-58.44% ROE
-58.44%
-42.27% ROA
-42.27%
-51.34% ROIC
-51.34%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Fate Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -186 M
Depreciation & Amortization 9.88 M
Capital Expenditures -730 K
Stock-Based Compensation 41.5 M
Change in Working Capital 0
Others 12 M
Free Cash Flow -124 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Fate Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for FATE of $4.75 , with forecasts ranging from a low of $3 to a high of $6 .
FATE Lowest Price Target Wall Street Target
3 USD 205.50%
FATE Average Price Target Wall Street Target
4.75 USD 383.71%
FATE Highest Price Target Wall Street Target
6 USD 511.00%
Price
Max Price Target
Min Price Target
Average Price Target
66554433221100Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Fate Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
605 K USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
2.68 K USD 1
Bought
0 USD 0
0-3 MONTHS
669 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2025 the Company granted restricted stock units (RSUs) representing 30,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. globenewswire.com - 2 weeks ago
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications globenewswire.com - 3 weeks ago
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus. zacks.com - 1 month ago
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) –   Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process globenewswire.com - 1 month ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. globenewswire.com - 1 month ago
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus. zacks.com - 2 months ago
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates Fate Therapeutics (FATE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago. zacks.com - 2 months ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE globenewswire.com - 2 months ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date. globenewswire.com - 2 months ago
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 months ago
Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: globenewswire.com - 3 months ago
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. seekingalpha.com - 3 months ago
8. Profile Summary

Fate Therapeutics, Inc. FATE

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 113 M
Dividend Yield 0.00%
Description Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Contact 12278 Scripps Summit Drive, San Diego, CA, 92131 https://www.fatetherapeutics.com
IPO Date Oct. 1, 2013
Employees 181
Officers Dr. Tunde Babalola Senior Vice President of Technical Operations Ms. Jessica Francis Vice President Of Human Resources & Operations Mr. Victor Hong Vice President of Corporate Development & Finance Dr. Yu Cai Head of Intellectual Property & Assistant General Counsel Dr. Bahram Valamehr M.B.A., Ph.D. President, Chief Executive Officer & Director Ms. Kate Duvall Corporate Controller Ms. Cindy R. Tahl J.D. Chief Legal & Compliance Officer and Corporate Secretary Mr. Andrew Henry Senior Vice President of Clinical Operations